17.10.2023 - Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce that data from the UNITE study presented today at the World Congress of Neurology in Montreal, Canada, show that AJOVY (fremanezumab) reduced migraine attacks and depression symptoms . Seite 1
Teva Pharmaceutical Industries Limited announced that data from the UNITE study presented at the World Congress of Neurology in Montreal, Canada, show that AJOVY® reduced migraine attacks and.
Almost half of all migraine patients experience depression and anxiety1
Migraine patients treated with AJOVY® showed significant reductions in depressive symptoms and clinically meaningful.
Teva Pharma (TEVA) Reports Phase IV UNITE Study Shows AJOVY Reduced Migraine Attacks and Depression Symptoms streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.